Printer Friendly

In vitro Susceptibility of Pseudomonas aeruginosa Isolated from Acute and Chronic Pulmonary Infection to Antibiotics, Lactobacillus Competition and Metal Nanoparticles.

Byline: Safia Rehman, Nazish Mazhar Ali, Gerald B. Pier, Iram Liaqat and Bushra Mazhar


Antibiotic resistance in Pseudomonas aeruginosa is a major barrier to successful treatment of infection. Additional and novel measures to control this pathogen are needed, along with contemporary information about antibiotic resistances that are present in isolates from different environments. In the present study 72 samples from blood, 43 from sputum, and 19 were obtained from tracheal aspirates patients suffering from chronic and acute lung infections admitted to a local hospital in Lahore. Susceptibility of 134 isolates of P. aeruginosa was tested against selected antibiotics (meropenem, imipenem, piperacillin, amoxicillin, amikacin, gentamicin, tobramycin, kanamycin, clarithromycin, clarithromycin, cefepime, cefixime, levofloxacin, and ciprofloxacin), Lactobacillus strains and metal nanoparticles (copper, ferric and zinc). P. aeruginosa isolates showed in vitro resistance against 11 of 14 antibodies tested.

The isolates were highly susceptible to meropenem, piperacillin, and amoxicillin. It was also observed that the growth of these resistant P. aeruginosa strains was significantly inhibited in the presence of Lactobacilli spp. and nanoparticles of silver, zinc and ferric oxide at a concentration of 12, 200 and 1ug/ml, respectively. This study may help in the development of chemotherapeutic methods against multidrug resistant bacterial pathogens in chronic and acute lung infections. It provides a practical approach towards the use of nanoparticles to enhance antimicrobial activity against these pathogens.

Key words

Antibacterial activity, Antibiotic, Lactobacilli, Nanoparticles, Pseudomonas aeruginosa, Pulmonary infections.


Bacterial infections cause morbidity and mortality in millions of people all over the world and also have a serious impact on the world economy (Oveisi et al., 2001; Thabit et al., 2015). The development of resistance against many clinically useful antibiotics has become alarming (Ferri et al., 2017). Antimicrobial resistance among Pseudomonas aeruginosa strains is a continuing and growing problem worldwide (Linden et al., 2003). P. aeruginosa has developed resistance to many antimicrobial agents including carbapenems, polymyxins, fluoroquinolones, cephalosporins, and aminoglycosides (Thabit et al., 2015). Newer approaches to control P. aeruginosa tissue colonization, spread and induction of disease are clearly needed.

One such approach might be the use of non-pathogenic bacterial strains with anti-P. aeruginosa activity that could be applied to sites of colonization such as burned skin, the oropharyngeal mucosa or the GI tract to inhibit P. aeruginosa colonization. Lactobacillus strains are well known for their probiotic role in medical science (Gordon et al., 1957). They produce bacteriocins, bioactive peptides with antimicrobial activity against Gram-positive bacteria such as Staphylococcus aureus, Bacillus cereus, Listeria monocytogenes and Clostridium botulinum (Nettles and Barefoot, 1993) and have been shown to protect mice against P. aeruginosa burn-wound infection (Argenta et al., 2016; Qamar et al., 2017).

Another approach is the use of silver ions, a practice that has had a major impact in reducing burn-wound infections by P. aeruginosa and other pathogens (Politano et al., 2013). Silver metal has a history of use in ayurvaidic medicine and other historical herbal treatments for infections (Alexander, 2009). Wilding et al. (2016) has reported this metal and its nanoparticles (AgNPs) efficiently inhibit the growth of Gram-positive and Gram-negative bacteria due to their antibacterial activity. Silver NPs were reported to be effective against bacterial cells by promoting cell wall lysis with release of intracellular contents, inhibiting cellular respiration and eventually damaging DNA (Li et al., 2011). The antibacterial activity of silver nanoparticles against pathogenic bacteria displayed the highest activity against Escherichia coli, Staphylococcus aureus, Pseudomonas aeruginosa, Bacillus subtilis, Klebsiella pneumoniae, and Proteus mirabilis (Buszewski et al., 2018).

This in vitro study was designed to evaluate the impact of lactobacilli, nanoparticles and different commercial antibiotics on multiple drug resistant clinical isolates of Pseudomonas aeruginosa obtained from patients in Lahore, Pakistan.


The blood, endotracheal aspirates and sputum samples were collected from patients with acute and chronic respiratory diseases (Table I) admitted in local government hospitals of Lahore, Punjab, Pakistan and the samples were transferred and processed in Department of Zoology, Government College University, Lahore. All the samples were collected using techniques as per international biomedical standards (Singh et al., 2015). Cetrimide agar was used for selective screening of P. aeruginosa strains (Fig. 1A). P. aeruginosa BS14 (KT721565) was used as a positive control for antibiotic testing.

The agar well diffusion method was used for susceptibility testing of P. aeruginosa against lactobacilli strains and nanoparticles. Lactobacilli were isolated from various food sources, and those isolated from yogurt were found to produce high quantities of bacteriocin-type toxins. These toxins have the ability to inhibit the growth of other bacterial strains. Nanoparticles of silver were used in aqueous (1mM AgNO3) solution.

Table I.- Clinical isolates of Pseudomonas aeruginosa showing age, sex and source of sampling.

Source###No. of###Female###Male###Age in


Blood, sputum###34###03###31###25-35

and endotracheal###47###11###36###36-45



Antagonistic properties of antibiotics against P. aeruginosa

P. aeruginosa isolates were cultured in brain heart infusion (BHI) broth following inoculation from a plate culture using a sterile cotton swab and incubated for 24 h at 37AdegC for preparation of a turbidity suspension of 0.5 McFarland units (0.5 McFarland turbidity standard provides an optical density comparable to the density of a bacterial suspension 1.5x 10^8 colony forming units (CFU/ml)). P. aeruginosa cultures were spread by adding 100 ul (~1.5 107cfu) of culture media onto sterile agar plates and antibiotic disks were placed on the plates at specific intervals to observe the antagonistic properties of the drugs against the isolates. Plates were incubated at 37AdegC for 24h and the zones of inhibition around the wells, in mm, measured. Susceptibilities were determined using standard Kirby-Bauer criteria (Hudzicki, 2009).

Antagonistic properties of lactobacilli against P. aeruginosa

P. aeruginosa isolates were cultured and suspended in BHI broth as described and 100 ul (1.5 x 107cfu) spread uniformly on sterile agar plates into 3-4 wells with 6 mm diameters had been previously cut with 20 mm distance between them. Strains of Lactobacillus were identified by using a universal primer for 16s ribosomal DNA (Forward primer 5`AGAGTTTGATCMTGGCTCAG 3` and reverse primer 5`TACGGYTACCTTGTTACGACTT3`). Lactobacilli were inoculated into MRS broth (a selective culture media for Lactobacilli) and incubated for 24 h at 37AdegC. Next, the culture was centrifuged at 5500 rpm (9000g) for 5 -10 min and the clear supernatant was used as an unpurified bacteriocin extract. Solutions (50 ul) were added into each 6 mm diameter well and sterile distilled water was used as a control. The plates were incubated at 37AdegC for 24 h and the zones of inhibition around the wells in mm measured. MRS broth was further used as negative control (Sgouras, 2004).

Anti-bacterial properties of nanoparticles against P. aeruginosa

The solutions of nanoparticles of several compounds were obtained from the chemistry department at GCU Lahore courtesy of Ms. Misbah Naz (Naz et al., 2017). Solutions of nanoparticles of silver nitrate, zinc oxide and ferric oxide with concentration of 12 ug/ml, 200 ug/ml and 1 ug/ml, respectively, were used to check the susceptibility of P. aeruginosa against these nanoparticles. P. aeruginosa colonies were spread on sterile agar plates and 3-4 wells of 6 mm diameter were made in a single plate with 20 mm distance between them. Fiftyul solutions of silver nitrate, ferric oxide, or zinc oxide orsterile distilled water as a control were added to wells. Plates were incubated at 37AdegC for 24 h and the zone of inhibition around the wells in mm measured (Hassan et al., 2014; Swaroop et al., 2015).


In the present study, a total of 134 isolates of P. aeruginosa were obtained from hospitalized patients and their antimicrobial susceptibility patterns, susceptibility to metal nanoparticles and inhibition by Lactobacillus determined. Figure 1B shows the media used for isolation and testing of the P. aeruginosa isolates for antibiotic sensitivity, nanoparticle sensitivity and susceptibility to Lactobacillus bacteriocins in culture supernates.

Table II.- Susceptibility of 134 P. aeruginosa strains to antibiotics.

Group / Antibiotic###R###I###S

(potency in ug)###n (%)###n (%)###n (%)


###Meropenem (MEM)10 ug###8 (6)###-###126 (94)

Imipenem (IRM) 10 ug###108 (81)###9 (7)###17 (13)


###Piperacillin (PIP) 30 ug###39 (29)###7 (5)###88 (66)

Amoxicillin (AX) 25 ug###5 (4)###17 (13)###111 (83)


###Amikacin (AK) 30 ug###50 (37)###21 (16)###63 (47)

###Gentamicin (GM) 10 ug###52 (39)###31 (23)###51 (38)

###Tobramycin (TN) 10 ug###105 (78)###-###29 (22)

Kanamycin (K) 30 ug###79 (59)###14 (10)###41 (31)


###Clarithromycin (CLA) 2ug 121 (90)###4 (3)###9 (7)

Erythromycin (E) 15 ug###90 (67)###20 (15)###24 (18)


###Cefepime (CPM) 30 ug###102 (76)###-###32 (24)

###Ceftazidime (CAZ) 10 ug###72 (54)###23 (17)###39 (29)

Cefixime (CFM) 5 ug###67 (50)###59 (44)###8 (6)

Gyrase inhibitors

###Levofloxacin (LEV) 1 ug###98 (73)###15 (11)###21 (16)

###Ciprofloxacin (CIP) 5 ug###102 (76)###11 (8)###21 (16)

Susceptibility of P. aeruginosa isolates to antibiotics

The Kirby-Bauer method was used to determine the antimicrobial susceptibilities of 134 clinical isolates of P. aeruginosa to clinically relevant and available antibiotics. Ninety-four percent of P. aeruginosa isolates were sensitive to meropenem but only thirteen percent susceptible to imipenem. There was relatively high susceptibility to penicillins ranging from 66%-83% but only moderate to low susceptibility to aminoglycosides (22%-47%). There was overall low susceptibility to the macrolides (7%-18%), cephalosporins (24%-29%) and gyrase inhibitors (7%-29%; Table II). Thus 66%-94% of the strains were susceptible to only 1 of the three antibiotics: meropenem, piperacillin or amoxicillin.

Antagonistic properties of lactobacilli against P. aeruginosa

The antibacterial activities of culture supernates from Lactobacillus delbruekii subsp. Bulgaricus (MH100728), Lactobacillus curvatus (MH107109) and Lactobacillus graminis (MH108629) were tested using the well-plate method. One-hundred percent of P. aeruginosa clinical isolates had zones of inhibition ranging from13 mm to 24 mm in diameter indicating they all had some potential susceptibility to factors in unpurified bacterial supernate from cultures of Lactobacilli strains containing 1x107 /mL (Fig. 1D).

Anti-bacterial properties of nanoparticles against P. aeruginosa

The well-in-plate method was used to determine the effects of nanoparticles on the growth of P. aeruginosa strains. The method is shown in Figure 1C. Clear zones of inhibition were obtained against the majority of the clinical isolates, indicating that nanoparticles had a strong deleterious effect on P. aeruginosa growth. Eighty percent of strains showed susceptibility to the nanoparticles (Table III), with clear zones of inhibition measured with average diameters of 9 mm. However, 20% of the clinical isolates showed growth in the presence of nanoparticles (Naz et al., 2017).

Table III.- Effect of nanoparticles on P. aeruginosa growth.


###n (%)###n (%)

Ag###12 ug/ml###111 (83)###23 (17)

ZnO###200 ug/ml###107 (80)###27 (20)

Fe2O3###100 ug/ml###103 (77)###31 (23)


To address issues of antibiotic resistances and potential countermeasures, their occurrence, geographic manifestations and potential for spread needs to be continuously monitored and reported. In this study we analyzed the antibiotic resistance profiles, susceptibility to nanoparticles and killing by anti-bacterial factors in supernates of common probiotic organisms against 134 clinical isolates of P. aeruginosa from Lahore, Pakistan. Fifty-four percent of the P. aeruginosa isolates were from blood, 32% from sputum and 14% from tracheal aspirates. Similar results had been reported in different studies from other regions (Arora et al., 2011). We found 66-94% of isolates were susceptible to meropenem or penicillins, and but had a high level of resistance to the macrolides (82%-93%), cephalosporins (71%-76%) and gyrase inhibitors (84%).

A more detailed analysis of the antibiotic-resistance findings showed strains of P. aeruginosa from the Lahore area hospitals are resistant to clarithromycin (90%), imipenem (81%), macrolides (84%) and tobramycin (78%) but are sensitive to meropenem (94%), amoxicillin (83%) and piperacillin (66%). In a Saudi Arabian hospital setting, Ahmad and Al-Harbi (2014) reported that there was a 70.7% susceptibility of P. aeruginosa isolates to meropenem but also concluded ciprofloxacin was the most active agent (85.4% susceptibility) against P. aeruginosa strains along with amikacin (95.1% susceptibility). They proposed that combinations of these antibiotics and [beta]-lactams are useful and should be tested in treating multi-drug resistant strains. However, among our patients there was low susceptibility to ciprofloxacin and amikacin, indicating a distinct pattern of resistances in P. aeruginosa isolates from this patient population.

Overall, in the Lahore hospital population, the P. aeruginosa isolates appear to have acquired a fairly high level of antibiotic resistances. In contrast, the majority of the isolates were killed by factors present in Lactobacillus probiotic supernates or by nanoparticles of either silver oxide, zinc oxide or ferric oxide, indicating two potential approaches for probiotic interventions or topical therapies to control drug-resistant P. aeruginosa colonization.

None of the antimicrobial agents were effective against all the multi-drug strains tested commiserates with the current worldwide problem in the treatment of multi-drug resistant nosocomial infections. In previous studies, P. aeruginosa isolates showed intermediate to full resistance against a variety of antimicrobial agents (Nicasio et al., 2008; Souli et al., 2008; Siegel, 2008; Giske et al., 2008; Slama, 2008; Chopra et al., 2008), encompassing clarithromycin, cefepime, ciprofloxacin, levofloxacin, imipenem tobramycin, amikacin, erythromycin, kanamycin, ceftazidime, and gentamicin. In our populations, many isolates were susceptible to meropenem, piperacillinor amoxicillin, indicating they represent the first-line drugs to consider in treating P. aeruginosa infections in the Lahore area hospitals.

Lactic acid bacteria are dispersed in nature and present in food items and are also found in vaginal flora where they promote resistance to urinary tract infections (UTI). Many strains of the genus Lactobacillus are also capable of colonizing the oral cavity and the gastrointestinal tracts and are important antagonists against certain pathogens (Antonio et al., 1999; Redondo-LoA'pez et al., 1990). The antimicrobial activity of strains of Lactobacillus against bacterial pathogens includes the production of bacteriocins, lactic acid and hydrogen peroxide (Servin, 2004). Bacteriocins inhibit the growth of susceptible microbial strains and can serve as signaling peptides or quorum sensing molecules (Dobson et al., 2012) or compete with pathogens for nutrients (Reid and Burton, 2002). Our results showed the presence of strong antibacterial activity in culture supernates of Lactobacillus delbruekii subsp.

Bulgaricus, Lactobacillus curvatus and Lactobacillus graminis ageists a majority of the P. aeruginosa nosocomial isolates. This initial finding suggests a potential for these organisms to serve a probiotics to prevent P. aeruginosa colonization of mucosal surfaces.

We also evaluated the susceptibility of the P. aeruginosa clinical isolates to silver, zinc and ferric oxide nanoparticles, additional potential topical therapeutics for this pathogen. Overall we found all three NPs tested inhibited the growth of the majority of P. aeruginosa strains from the current study. Bayroodi and Jalal (2016) reported that the antimicrobial effects of AgNP could be enhanced by synergism with ZnO NPs when co-evaluated against resistant bacterial strains. Brayner et al. (2006) and Tam et al. (2008) reported damage to the membrane of bacterial cells by the ZnO NPs, resulting in leakage of the contents to the outside of the cell. Complexes of ciprofloxacin with copper II and zinc II showed higher antibacterial activity against P. aeruginosa than ciprofloxacin alone (Anacona and Toledo, 2001). Overall, NPs either alone or in combination with antibiotics present another therapeutic option for treating multi-resistant P. aeruginosa infections.

In terms of demographics, the patients in this study were between the ages of 25 to 55 years, indicating a relatively young population in this cohort experiencing clinically significant P. aeruginosa infection. Almost 80% of our patients were male. This tends to reflect the gender demographic in many studies of P. aeruginosa infection outside of CF. However, Nadeem et al. (2009) reported in his study of a total of 1008 isolates of P. aeruginosa that 532 isolates were from male patients (52.7%; 504 adults and 28 children), and 476 isolates were from female patients (47.9%; 442 adults and 34 children). The gender distribution of P. aeruginosa reported by Ali et al. (2015) indicated 66.2% of the isolates of P. aeruginosawere from males, and the incidence of multidrug resistant P. aeruginosa in males was reported as 72.1%. Notably, the most susceptible age group was reported to be 10-19 years old.

Although 80% of the P. aeruginosa isolates in this study were from patients 0-60 years old, in other studies (Ahmed and Al-Harbi, 2014), a higher rate of P. aeruginosa infections was reported among elderly (61-80 years old) patients. Overall, while P. aeruginosa nosocomial infections are often associated with males over 60 years of age it is clear this can vary among different hospitalized populations.


Sixty-six to >90 percent of the total P. aeruginosa isolates from the Lahore region showed in vitro resistance to many of the commercially available antibiotics tested. Meropenem, piperacillin, and amoxicillin were the drugs for which there was the greatest susceptibility and represent recommended treatments for infections due to P. aeruginosa in our region. A significant killing of these resistant P. Aeruginosa strains by factors present in supernates of Lactobacilli spp. was observed, suggesting that the use of Lactobacilli spp. as probiotics may be of value for the treatment or prevention of P. aeruginosa colonization. We also found strong in vitro anti-bacterial efficacy of Ag, Zn and Fe3 oxide NPs against the local P. aeruginosa isolates, suggestive of additional research into their practical application in a healthcare department.


This study was supported by Govt. College University Lahore, Pakistan.

Statement of conflict of interest

I have declared no conflict of interest.


Ahmed, S. and Al-Harbi, M.N., 2014. Antibiotic susceptibility pattern of isolates of Pseudomonas aeruginosa in a Saudi Arabian Hospital. Bangladesh J. med. Sci., 13: 45-48.

Alexander, J.W., 2009. History of the medical use of silver. Sur. Infec. 10: 289-292.

Ali, Z., Mumtaz, N., Naz, S.A., Jabeen, N. and Shafique, M., 2015. Multi-drug resistant Pseudomonas aeruginosa: A threat of nosocomial infections in tertiary care hospitals. J. Pakistan med. Assoc., 65: 12-16.

Anacona, J.R. and Toledo, C., 2001. Synthesis and antibacterial activity of metal complexes of ciprofloxacin. Trans. Metal Chem., 26: 228-231.

Antonio, M.A., Hawes, S.E. and Hillier, S.L., 1999. The identification of vaginal Lactobacillus species and the demographic and microbiologic characteristics of women colonized by these species. J. Infect. Dis., 180: 1950-1956.

Argenta, A., Satish, L., Gallo, P., Liu, F. and Kathju, S., 2016. Local application of probiotic bacteria prophylaxes against sepsis and death resulting from burn wound infection. PLoS One, 11: e0165294.

Arora, D., Jindal, N. and Kumar, R., 2011. Romit. Emerging antibiotic resistance in Pseudomonas aeruginosa. Int. J. Pharm. Pharmaceut. Sci., 3: 82-84.

Bauer, A.W., Kirby, W.M., Sherris, J.C. and Turck, M., 1966. Antibiotic susceptibility testing by a standardized single disk method. Am. J. clin. Pathol., 45: 493-496.

Bayroodi, E. and Jalal, R., 2016. Modulation of antibiotic resistance in Pseudomonas aeruginosa by ZnO nanoparticles. Iranian J. Microbiol., 8: 85-92.

Brayner, R., Ferrari-Iliou, R., Brivois, N., Djediat, S., Benedetti, M.F. and Fievet, F., 2006. Toxicological impact studies based on Escherichia coli bacteria in ultrafine ZnO nanoparticles colloidal medium. Nano Lett., 6: 866-870.

Buszewski, B., Railean-Plugaru, V., Pomastowski, P., Rafinska, K., Szultka-Mlynska, M., Golinska, P., Wypij, M., Laskowski, D. and Dahm, H., 2018. Antimicrobial activity of biosilver nanoparticles produced by a novel Streptacidiphilus durhamensis strain. J. Microbiol., Immunol. Infect., 51: 45-54.

Chopra, I., Schofield, C., Everett, M., O'Neill, A., Miller, K., Wilcox, M., Frere, J.M., Dawson, M., Czaplewski, L., Urleb, U. and Courvalin, P., 2008. Treatment of health-care-associated infections caused by Gram-negative bacteria: A consensus statement. Lancet Infect. Dis., 8: 133-139.

Dobson, A., Cotter, P.D., Ross, R.P. and Hill, C., 2012. Bacteriocin production: A probiotic trait? Appl. environ. Microbiol., 78: 1-6.

Ferri, M., Ranucci, E., Romagnoli, P. and Giaccone, V., 2017. Antimicrobial resistance: A global emerging threat to public health systems. Rev. Fd. Sci. Nnutr., 57: 2857-2876.

Gencer, S., Ak, O., Benzonana, N., Batirel, A. and Ozer, S., 2002. Susceptibility patterns and cross resistances of antibiotics against Pseudomonas aeruginosa in a teaching hospital of Turkey. Annls. clin. Microbiol. Antimicrob., 1: 2-4.

Giske, C.G., Monnet, D.L., Cars, O. and Carmeli, Y., 2008. Clinical and economic impact of common multidrug-resistant gram-negative bacilli. Antimicrob. Agents Chemother., 52: 813-821.

Gordon, D., Macbae, J. and Wheater, D.M., 1957. A Lactobacillus preparation for use with antibiotics. The Lancet, 269: 899-901.

Hassan, A.A., Oraby, N.A., Mohamed, A.A. and Mahmoud, H.H., 2014. The possibility of using zinc oxide nanoparticles in controlling some fungal and bacterial strains isolated from buffaloes. Egypt. J. appl. Sci., 29: 58-83.

Hudzicki, J., 2009. Kirby-Bauer disk diffusion susceptibility test protocol. American Society for Microbiology, pp. 1-22.

Li, W.R., Xie, X.B., Shi, Q.S., Duan, S.S., Ouyang, Y.S. and Chen, Y.B., 2011. Antibacterial effect of silver nanoparticles on Staphylococcus aureus. Biometals, 24: 135-141.

Linden, P.K., Kusne, S., Coley, K., Fontes, P., Kramer, D.J. and Paterson, D., 2003. Use of parenteral colistin for the treatment of serious infection due to antimicrobial-resistant Pseudomonas aeruginosa. Clin. Infect. Dis., 37: e154-e160.

Nadeem, S., Qasmi, S., Afaque, F., Saleem, M., Nadeem, S.H.S. and Hakim, S., 2009. Comparison of the in vitro susceptibility of clinical isolates of Pseudomonas aeruginosa in a local hospital setting in Karachi, Pakistan. Br. J. med. Pract., 2: 35-39.

Naz, M., Haider, A., Ikram, M., Qureshi, M.Z. and Ali, S., 2017. Green synthesis (A. indica seed extract) of silver nanoparticles (Ag-NPs), characterization, their catalytic and bactericidal action potential. Nanosci. Nanotechnol. Lett., 9: 1649-1655.

Nettles, C.G. and Barefoot, S.F., 1993. Biochemical and genetic characteristics of bacteriocins of food-associated lactic acid bacteria. J. Fd. Protec., 56: 338-356.

Nicasio, A.M., Kuti, J.L. and Nicolau, D.P., 2008. The current state of multidrug-resistant gram-negative bacilli in North America. J. Human Pharmacol. Drug Ther., 28: 235-249.

Oveisi, H., Rahighi, S., Jiang, X., Agawa, Y., Beitollahi, A., Wakatsuki, S. and Yamauchi, Y., 2011. Improved inactivation effect of bacteria: Fabrication of mesoporous anatase films with fine Ag nanoparticles prepared by coaxial vacuum arc deposition. Chem. Lett., 40: 420-422.

Politano, A.D., Campbell, K.T., Rosenberger, L.H. and Sawyer, R.G., 2013. Use of silver in the prevention and treatment of infections: Silver review. Surg. Infect., 14: 8-20.

Redondo-Lopez, V., Cook, R.L. and Sobel, J.D., 1990. Emerging role of lactobacilli in the control and maintenance of the vaginal bacterial microflora. Rev. Infect. Dis., 12: 856-872.

Qamar, M.U., Saleem, S., Arshad, U., Rasheed, M.F., Ejaz, H., Shahzad, N. and Shah, J., 2017. Antibacterial efficacy of Manuka honey against New Delhi Metallo-[beta]-Lactamase producing gram negative bacteria isolated from blood cultures. Pakistan J. Zool., 49: 1997.2003.

Reid, G. and Burton, J., 2002. Use of Lactobacillus to prevent infection by pathogenic bacteria. Microb. Infect., 4: 319-324.

Servin, A.L., 2004. Antagonistic activities of lactobacilli and bifidobacteria against microbial pathogens. FEMS Microbiol. Rev., 28: 405-440.

Siegel, R.E., 2008. Emerging gram-negative antibiotic resistance: Daunting challenges, declining sensitivities, and dire consequences. Respir. Care, 53: 471-479.

Silva-Santos, K., Barbosa, A.M., Pereira da Costa, L., Pinheiro, M.S., Oliveira, M.B.P.P. and Ferreira-Padilha, F., 2016. Silver nano-composite biosynthesis: Antibacterial activity against multidrug-resistant strains of Pseudomonas aeruginosa and Acinetobacter baumannii. Molecules, 21: 1255-1261.

Singh, I., Jaryal, S.C., Thakur, K., Sood, A., Grover, P.S. and Bareja, R., 2015. Isolation and characterization of various Pseudomonas species from distinct clinical specimens. IOSR J. Dental med. Sci., 14: 80-84.

Slama, T.G., 2008. Gram-negative antibiotic resistance: There is a price to pay. Crit. Care, 12: 1-7.

Sgouras, D., Maragkoudakis, P., Petraki, K., Martinez-Gonzalez, B., Eriotou, E., Michopoulos, S., Kalantzopoulos, G., Tsakalidou, E. and Mentis, ., 2004. In vitro and in vivo inhibition of Helicobacter pylori by Lactobacillus casei strain Shirota. Appl. Environ. Microbiol., 70: 518-526.

Souli, M., Galani, I. and Giamarellou, H., 2008.Emergence of extensively drug-resistant and pandrug-resistant Gram-negative bacilli in Europe. Eurosurveillance, 13: 19045-19056.

Swaroop, K., Sheikh, S., Chandrashekar, K.R. and Somashekarappa, H., 2015. Antibacterial studies of gamma irradiated zinc oxide nanoparticles on Klebsiella pneumonia and Pseudomonas aeruginosa. IOSR J. appl. Physiol., 7: 58-63.

Tam, K.H., DjuriA!ic, A.B., Chan, C.M.N., Xi, Y.Y., Tse, C.W., Leung, Y.H., Chan, W.K., Leung, F.C.C. and Au, D.W.T., 2008. Antibacterial activity of ZnO nanorods prepared by a hydrothermal method. Thin Solid Films, 516: 6167-6174.

Thabit, A.K., Crandon, J.L. and Nicolau, D.P., 2015. Antimicrobial resistance: impact on clinical and economic outcomes and the need for new antimicrobials. Exp. Opin. Pharmacother., 16: 159-177.

Wilding, L.A., Bassis, C.M., Walacavage, K., Hashway, S., Leroueil, P.R., Morishita, M., Maynard, A.D., Philbert, M.A. and Bergin, I.L., 2016. Repeated dose (28-day) administration of silver nanoparticles of varied size and coating does not significantly alter the indigenous murine gut microbiome. Nanotoxicology, 10: 513-520.
COPYRIGHT 2018 Asianet-Pakistan
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2018 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Author:Rehman, Safia; Ali, Nazish Mazhar; Pier, Gerald B.; Liaqat, Iram; Mazhar, Bushra
Publication:Pakistan Journal of Zoology
Article Type:Clinical report
Date:Dec 31, 2018
Previous Article:Influence of Different Weaning Ages on Growth Performance of Achai Crossed Jersey Calves.
Next Article:Complete Mitochondrial Genome of Three Species (Perciformes, Amblyopinae): Genome Description and Phylogenetic Relationships.

Terms of use | Privacy policy | Copyright © 2022 Farlex, Inc. | Feedback | For webmasters |